PRGO Perrigo Co Plc
Updated
Healthcare · Pharmaceutical Preparations
Perrigo Co Plc (PRGO) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $2.0 billion. Shares last traded at $14.26, 39.8% below their 52-week high. Over the past year the stock is down 38.9%. Net profit margin is -41.9%, below the peer median of -8.9%. Revenue declined 2.8% year over year. The shares yield 8.1% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-27 · SEC EDGAR/XBRL.
PRGO Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $159M | $1.15 | — |
| 2024-12-31 | $153M | $1.11 | — |
| 2023-12-31 | $150M | $1.11 | — |
| 2022-12-31 | $142M | $1.06 | — |
| 2021-12-31 | $130M | $0.97 | — |
| 2020-12-31 | $124M | $0.90 | — |
| 2019-12-31 | $112M | $0.82 | 77% |
| 2018-12-31 | $105M | $0.76 | 80% |
| 2017-12-31 | $91M | $0.64 | 76% |
| 2016-12-31 | $83M | $0.58 | — |
| 2015-06-27 | $65M | $0.46 | 48% |
| 2014-06-28 | $46M | $0.40 | 20% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-2.33 | 2026-08-05 |
| Q1 2026 | $-2.87 | 2026-05-06 |
| FY 2025 | $-10.29 | 2026-02-26 |
| Q3 2025 | $-0.05 | 2025-11-05 |
| Q2 2026 | $-0.10 | 2026-08-05 |
| Q1 2026 | $-0.05 | 2026-05-06 |
Pharmaceutical Preparations peers
PRGO vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.